Blot William J, Fischer Thomas, Nielsen Gunnar Lauge, Friis Søren, Mumma Michael, Lipworth Loren, DuBois Raymond, McLaughlin Joseph K, Sørensen Henrik T
International Epidemiology Institute, Rockville, Maryland, USA.
Pharm World Sci. 2004 Dec;26(6):319-23. doi: 10.1007/s11096-004-9008-5.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to increase the risk of upper gastrointestinal bleeding (UGIB). Whether the severity of outcome of UGIB associated with NSAIDs differs from non-NSAID-related UGIB is less clear.
Medical records of 228 patients hospitalized for UGIB in the Danish county of North Jutland were evaluated. Preadmission characteristics and clinical outcomes were compared between 112 patients who had been prescribed ibuprofen and 116 patients who had been prescribed paracetamol within 90 days of the hospitalization.
The baseline characteristics of UGIB patients prescribed ibuprofen tended to differ from those prescribed paracetamol. The ibuprofen group significantly less often had histories of ulcer (11% vs 36%) and dyspepsia (19% vs 44%), or had been prescribed medications for these or other conditions, and had lower co-morbidity indices. Ibuprofen users also were somewhat less likely (31% vs 37%) to report GI pain at admission, but among hospitalized patients with endoscopic examinations were more likely (75% vs 58%) to be diagnosed with ulcer or hematemesis vs normal or gastritis/dyspepsia/reflux. For the clinical outcomes, 30 days case fatality rates were 12% for both ibuprofen and paracetamol users. The ibuprofen-related cases of UGIB more often required surgery (11% vs 3%) or transfusions (66% vs 57%), and those prescribed ibuprofen averaged 11 days in hospital, 4 days longer than those prescribed paracetamol. Adjustment for baseline characteristics and underlying conditions, or analyses eliminating patients with unconfirmed diagnoses and prior ulcers or restricted to patients with current hospital diagnoses of ulcer or hematemesis, did not materially alter the ibuprofen vs paracetamol differences in outcome measures. Generally similar results were obtained when restricting the analyses to patients prescribed ibuprofen or paracetamol within 30 days of UGIB hospitalization, except for a reduction in the 30 days case fatality rate among those prescribed ibuprofen.
UGIB patients with antecedent ibuprofen prescriptions experienced about the same case fatality rates, but more surgery and longer hospital stays, than patients prescribed paracetamol. The differences appear in part due to differing characteristics among those prescribed ibuprofen compared with those prescribed paracetamol, but also raise the possibility of drug-related effects.
已知非甾体抗炎药(NSAIDs)会增加上消化道出血(UGIB)的风险。与非NSAIDs相关的UGIB相比,NSAIDs相关UGIB的结局严重程度是否不同尚不清楚。
对丹麦北日德兰郡因UGIB住院的228例患者的病历进行评估。比较了112例在住院前90天内开具布洛芬处方的患者和116例开具对乙酰氨基酚处方的患者的入院前特征和临床结局。
开具布洛芬处方的UGIB患者的基线特征往往与开具对乙酰氨基酚处方的患者不同。布洛芬组有溃疡病史(11%对36%)、消化不良病史(19%对44%)或因这些或其他疾病开具药物治疗的情况明显较少,且合并症指数较低。布洛芬使用者入院时报告胃肠道疼痛的可能性也略低(31%对37%),但在内镜检查的住院患者中,被诊断为溃疡或呕血的可能性更高(75%对58%),而不是正常或胃炎/消化不良/反流。就临床结局而言,布洛芬和对乙酰氨基酚使用者的30天病死率均为12%。布洛芬相关的UGIB病例更常需要手术(11%对3%)或输血(66%对57%),开具布洛芬处方的患者平均住院11天,比对乙酰氨基酚使用者长4天。对基线特征和潜在疾病进行调整,或对未确诊诊断和既往溃疡患者进行分析,或仅限于目前医院诊断为溃疡或呕血的患者,并未实质性改变布洛芬与对乙酰氨基酚在结局指标上的差异。当将分析限制在UGIB住院前30天内开具布洛芬或对乙酰氨基酚处方的患者时,除了开具布洛芬处方的患者30天病死率有所降低外,获得了大致相似的结果。
与开具对乙酰氨基酚处方的患者相比,有布洛芬处方史的UGIB患者病死率大致相同,但手术更多,住院时间更长。这些差异部分似乎是由于开具布洛芬处方的患者与开具对乙酰氨基酚处方的患者特征不同,但也增加了药物相关影响的可能性。